SEC Form 4 · accession 0001213900-17-010746
Enochian Biosciences Inc · ENOB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rene Sindlev
Director · 10% Owner
Period of report
Oct 13, 2017
Accepted (ET)
Oct 19, 2017 · 6:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001527728
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants to purchase shares of common stockF1 | $2.00 | Oct 13, 2017 | P | 250,000 | A | Oct 13, 2017 | Dec 31, 2019 | Common Stock | 250,000 | 5,650,000 | I |
Explanation of responses
- F1On October 13, 2017, RS Group ApS, an entity controlled by Mr. Sindlev, purchased 250,000 warrants to purchase shares of common stock of Dandrit Biotech USA, Inc. in a private transaction.